We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+33.5%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.54B
AUM Growth
+$235M
Cap. Flow
+$123M
Cap. Flow %
7.98%
Top 10 Hldgs %
73.5%
Holding
35
New
4
Increased
4
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$79.5M
2
IMMU
Immunomedics Inc
IMMU
+$62.7M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$45.3M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$42.2M
5
TGTX icon
TG Therapeutics
TGTX
+$24.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$127M
2
GYRE icon
Gyre Therapeutics
GYRE
+$13.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.37M
4
VKTX icon
Viking Therapeutics
VKTX
+$8.87M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 92.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.11B
$287M 18.66%
7,512,049
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.6B
$282M 18.31%
4,240,536
– –
SLDB icon
3
Solid Biosciences
SLDB
$798M
$95.8M 6.22%
179,296
– –
ECYT
4
DELISTED
Endocyte, Inc. Common Stock
ECYT
$78M 5.06%
5,649,884
+1,768,091
+46% +$21M
MNTA
5
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$75.7M 4.92%
+3,702,533
New +$79.5M
IMMU
6
DELISTED
Immunomedics Inc
IMMU
$73.8M 4.79%
+3,119,778
New +$62.7M
MYOV
7
DELISTED
Myovant Sciences Ltd.
MYOV
$64.7M 4.2%
2,830,455
– –
IFRX icon
8
InflaRx
IFRX
$247M
$63.4M 4.12%
1,967,148
+346,495
+21% +$12M
TGTX icon
9
TG Therapeutics
TGTX
$8.14B
$56.3M 3.65%
4,278,796
+1,806,452
+73% +$24.8M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$54.9M 3.57%
350,933
-2,200
-0.6% -$345K
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$50.6M 3.29%
1,145,268
– –
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7.27B
$48.2M 3.13%
+1,541,743
New +$42.2M
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$48.2M 3.13%
3,933,489
– –
EIDX
14
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$44M 2.86%
+2,162,671
New +$45.3M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.42B
$40M 2.6%
6,984,692
– –
RARX
16
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$38.3M 2.49%
3,851,808
– –
KALA icon
17
KALA BIO
KALA
$13M
$29M 1.88%
846
– –
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$19.8M 1.29%
900,000
– –
CLSD
19
DELISTED
Clearside Biomedical
CLSD
$16.3M 1.06%
101,667
– –
SCPH
20
DELISTED
scPharmaceuticals
SCPH
$16.2M 1.05%
2,857,143
– –
IOVA icon
21
Iovance Biotherapeutics
IOVA
$2.03B
$14.4M 0.93%
1,121,153
+462,094
+70% +$6.75M
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$11.7M 0.76%
1,441,070
– –
AVEO
23
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$11.4M 0.74%
506,276
– –
SPRO icon
24
Spero Therapeutics
SPRO
$68.3M
$10.9M 0.71%
741,647
– –
CBIO
25
Crescent Biopharma
CBIO
$550M
$4.09M 0.27%
2,535
– –
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, RA Capital Management held 35 positions worth $1.54B, up 18% from $1.31B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

RA Capital Management deployed $123M of net new capital in Q2 2018, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Momenta Pharmaceuticals, Inc.: 3,702,533 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $345K trimmed.

  • RA Capital Management's largest Q2 2018 buy was Momenta Pharmaceuticals, Inc.: 3,702,533 shares worth $75.7M.
  • RA Capital Management added most to TG Therapeutics in Q2 2018, an estimated $24.8M increase.
  • RA Capital Management's biggest Q2 2018 reduction was Sage Therapeutics, cutting an estimated $345K.
  • RA Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $127M.
  • RA Capital Management's ten largest holdings make up 74% of its $1.54B portfolio in Q2 2018.
  • RA Capital Management opened 4 new positions and closed 8 in Q2 2018.
  • RA Capital Management's portfolio value rose 18% quarter-over-quarter to $1.54B.

Based on RA Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.